Company: INDP
Filing Date: 2025-07-29
Form Type: 8-K
Source: 0001641172-25-021377
Chunk: 0

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-07-29
Form: 8-K
Item: Item 3.02
Chunk 0
---
Item
3.02. Unregistered Sales of Equity Securities.

As
previously reported on its Current Reports on Form 8-K filed on June 13, 2025 and July 1, 2025, Indaptus Therapeutics, Inc. (the “ Company”)
completed a private placement (the “ Private Placement”) of convertible promissory notes (the “ Notes”) and warrants
(the “ Warrants”) to certain accredited investors (the “ Purchasers”) in two closings on June 12, 2025 and June
30, 2025, for total gross proceeds of approximately $5.7 million, before deducting the placement agent’s fees and other offering
expenses.

In
accordance with the terms of the Notes, on July 27, 2025 (the “ Conversion Date”), the Notes were automatically converted
into an aggregate of 545,598 shares (the “ Conversion Shares”) of the Company’s common stock, par value $0.01 per share
(the “ Common Stock”), based on a conversion price of $8.3024, which is equal to 80% of the average Nasdaq closing price for
the five trading days immediately preceding and including the Conversion Date. In addition, for Purchasers whose conversions would have
exceeded ownership limits of 4.99% or 9.99%, the Company issued pre-funded warrants to purchase an aggregate of 146,763 shares
of Common Stock (the “ Pre-Funded Warrants”) which represent the portion that would otherwise exceed the applicable threshold.
The Pre-Funded Warrants have substantially the same terms as the Warrants, but with an exercise price for the Pre-Funded Warrants of
$0.01 per share and no expiration date.

In
connection with the automatic conversion of the Notes, the Company issued to the Purchasers Warrants to purchase an aggregate
of 1,384,722 shares of Common Stock exercisable at $8.3024 per share and with a term ending on July 27, 2030. In addition, the Company
issued to Paulson Investment Company, Inc. (“ Paulson”) and its designees placement agent warrants (the “ Placement
Agent Warrants”) to purchase an aggregate of 83,083 shares of Common Stock. The Placement Agent Warrants have the same terms as
the Warrants (except that the Placement Agent Warrants contain a cashless exercise feature that is not dependent on the registration
of the underlying shares)